Small Business Special Programs
Expedites the decision and award of Phase II funding for scientifically meritorious applications that have a high potential for commercialization. The goals for phase II must be clear and the likelihood of phase I success high to be competitive.
- Fast-Track Applications: PHASE I + II parallel review option:
- Phase I and Phase II submitted and reviewed together - See NOT-OD-06-004 for more information
- Milestone review before Phase II funding
Phase IIB Competing Renewal Awards
NIDDK will accept Phase IIB SBIR/STTR Competing Renewal grant applications from NIDDK supported Phase II awardees that propose to continue the process of developing products that ultimately require 1) clinical evaluation, 2) approval by a Federal regulatory agency, and 3) continuing refinements to durable medical equipment (DME) designs such as cost reduction, testing for safety, durability, and reliability, and meeting or establishing standards. This renewal grant should allow small businesses to get to a stage where interest and investment by third parties is more likely. Such products include, but are not limited to biological products, devices, drugs, medical implants, etc. related to the mission of the NIDDK. The previously funded Phase II SBIR/STTR grant need not have been submitted in response to a particular solicitation, as long as the research is appropriate to the purpose of this solicitation. Budgets up to $1,000,000 total costs per year and time periods up to 3 years may be requested. Contact NIDDK staff for more information.
Commercial Assistance Program (CAP)
The NIH CAP is a specialized technical assistance program for SBIR/STTR Phase II awardees. CAP is designed to help promising small life science companies develop their commercial businesses and transition their SBIR/STTR - developed technologies into the marketplace. It is a 3-9 month program of training workshops, individual mentoring and consulting sessions, and public events in which companies present their technologies to the biomedical and biotechnology investment communities, potential strategic partners, and licensees. The program begins each fall. See NIH CAP for more information.
SBIR Niche Assessment Program
The SBIR Niche Assessment Program was created to identify market issues such as the needs and concerns of end-users, competing technologies and products, the competitive advantage of the technology, key competitors, potential customers and commercialization partners, and a suggested a commercialization strategy that includes tasking and a schedule for implementation. NIH has contracted with Foresight Science and Technology to perform Technology Niche Analyses (TNA™) for 150 NIH SBIR Phase I awardees who received awards in fiscal years 2013 and 2014. The TNA™ will assess potential uses of the technology and result in a report that addresses the end-user needs and more. For a full description of the program, check the NIH Guide Notice NOT-OD-13-109.
Page last updated: September 23, 2013